The agreement is expected to provide Quay, which was established in 2002, with the investment needed to further develop its broad range of services and capabilities to support clients through the various stages of pharmaceutical clinical development, from preclinical to clinical trial. formulation, dosage form design and optimization, as well as the manufacture and supply of clinical trials.
Quay Pharma CEO Maireadh Pedersen said that, as part of SGS, CDMO will be able to accelerate its growth strategy and further develop its range of services, with the introduction of additional capabilities such as the biopharmaceutical analysis and specialized microbiological capabilities.
“At the same time, we will retain our current leadership and dedicated specialist teams to ensure we continue to provide our customers with the highest levels of service, expertise and technical focus. “
In particular, the parties said, the agreement will strengthen the continued development of Quay “innovative”Work in living biotherapy (LPB). LPBs focus on using microbes to elicit a pharmaceutical response, specifically targeted at the immune system.
According to Quay, this was the first globally licensed CDMO capable of supporting this new area of pharmaceutical therapies.
Formulation development and clinical manufacturing
The company, which works with both small and large molecules, said it has also built a solid reputation for the development of formulations and the clinical manufacture of unusual and difficult-to-handle drug substances.
It continued to invest to support the ongoing expansion. In December 2020, it established its operations in the United States, opening a development and manufacturing facility in the Greater Boston area, while October 2020 saw Quay expand its operations in the United Kingdom, with a new laboratory and offices located close to its UK headquarters at Deeside Industrial Park. .
The CDMO will be part of SGS Health Science and will be the company’s global center of excellence for formulation, research and development. The acquisition is part of SGS ‘strategy to expand its range of services to support customers throughout the health sciences supply chain.
Frankie Ng, CEO of SGS, said the move would further align the Swiss group’s global network with ICT megatrends. “Quay Pharma adds a significant level of competence to the group and allows us to offer our clients more complete and complex services, with high added value.